Highlights
- 1Journal of medicinal chemistry · 2022
- 2ACS medicinal chemistry letters · 2021
Publications
Funding
Active
3 grants- Co-IP50HD123367-01Advancing an ADCY10 inhibitor on-demand male contraceptive into humansEunice Kennedy Shriver National Institute of Child Health and Human Development · 2026–2030
- Co-IR01HD111549-01A1Optimization of lead candidates for an on-demand male contraceptiveEunice Kennedy Shriver National Institute of Child Health and Human Development · 2023–2028
- Co-IP50HD113015-01On-demand nonhormonal male contraception via ADCY10 inhibitionEunice Kennedy Shriver National Institute of Child Health and Human Development · 2023–2026
Completed grants (1)
- Co-IP50HD100549-03On-Demand Pharmacological Contraception by Blocking ADCY 10Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2019–2022
News mentions
- Weill Cornell Medicine Receives NIH Grant to Test Novel Male ContraceptiveOctober 23, 2026
Weill Cornell Medicine has received a four-year, $8.2 million grant from the National Institute of Child Health and Human Development (NICHD) to develop and test an experimental on-demand male contraceptive pill that temporarily stops sperm in their tracks.
- Dr. Teresa Sanchez Awarded the Established Investigator Award from the American Heart AssociationJune 12, 2025
Dr. Teresa Sanchez, associate professor of pathology and laboratory medicine and associate professor of neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine, has been awarded the highly competitive Established Investigator Award from the American Heart Association.
- NIH Center Grant Bolsters Male Contraceptive ResearchSeptember 21, 2023
Weill Cornell Medicine has received a three-year, nearly $6 million grant to lead one of three national contraceptive research centers.
External relationships
Leadership Roles
Meinke Pharma Consulting, LLC · Sacyl Pharmaceuticals, Inc.
Ownership
FemFort Contraception LLC · Meinke Pharma Consulting, LLC · Sacyl Pharmaceuticals, Inc.
Proprietary Interest
Sacyl Pharmaceuticals, Inc.